New clinical PK/PD modelling service

RNS Number : 1592A

Physiomics PLC

18 March 2013

 



Physiomics plc

(the "Company" or "Physiomics")

Physiomics to provide clinical PK/PD modelling services

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce the launch if its new clinical PK/PD modelling service.  Large pharmaceutical and biotechnology companies routinely outsource clinical PK/PD work, which is used primarily to determine the appropriate dosing and scheduling of a drug in man to maximise beneficial effects and minimise unwanted side effects.

Physiomics has entered this field because it supports the Clinical version of the Virtual Tumour currently being developed and also because it now has experience of phase I/II PK/PD modelling in-house.

Dr Mark Chadwick, CEO of Physiomics, commented:  "This new service represents an important step towards applying all of our models to the clinical setting. By engaging with clinical project managers we aim to generate service revenue and also pave the way for future collaborations incorporating Virtual Tumour Clinical in particular."

Enquiries:

Physiomics plc                                                  

Mark Chadwick 

[phone]

WH Ireland Limited

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

 Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

 Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

NRAJAMATMBMBBPJ